Report a data issue, formatting problem, or request follow-up. Our team responds within one business day.
Be the first to review this report.
Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.
Global Viral Vector and Plasmid DNA key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Europe, and Asia-Pacific, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections, etc.
This report quantifies the global Viral Vector and Plasmid DNA market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Viral Vector and Plasmid DNA.
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Viral Vector and Plasmid DNA companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
You may also be interested in
